ESMO Breast Cancer 2025

Regístrate para poder visualizar todo el contenidos de ESMO Breast Cancer 2025. 
Si todavía no estás registrado, puedes hacerlo aquí.

Si ya estás registrado, pulsa en Acceder.

Highlights pre-Congress

HER2

LBA1 - APHINITY: Final analysis at 11.3 years’ median follow-up

Author: Sibylle Loibl (Neu-Isenburg, Germany) 

Session: Proffered Paper Session 2 

Date/Time: 15.05.2025 15:00-15:13 

Location: Room 14 

Clinical outcomes in patients (pts) with stage cT1/T2cN0 HER2[+] breast cancer (BC) treated with neoadjuvant trastuzumab and pertuzumab (HP): An exploratory analysis from the PHERGain trial

Author: Jose Manuel Perez Garcia (Barcelona, Spain) 

Session: Poster Display session 

Date/Time: 15.05.2025 12:00 - 12:45 

Location: Hall B0 

Real-World Evidence of Trastuzumab and Pertuzumab with Taxanes or Vinorelbine as a First-Line Treatment for HER2-Positive Metastatic Breast Cancer

Author: Raquel Delgado Garcia (Seville, Spain) 

Session: Poster Display session 

Date/Time: 15.05.2025 12:00 - 12:45 

Location: Hall B0 

Anaphylaxis/hypersensitivity with the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in HER2-positive breast cancer (HER2+ BC)

Author: Sara M. Tolaney (Boston, MA, United States of America) 

Session: Poster Display session 

Date/Time: 15.05.2025 12:00 - 12:45 

Location: Hall B0 

TNBC

LBA3 - Primary results from EL1SSAR, a prospective phase 3b study of first-line atezolizumab (atezo) plus nab-paclitaxel (nPac) therapy for patients (pts) with PD-L1+ advanced triple-negative breast cancer (aTNBC)

Author: Suzette Delaloge 

Session: Mini Oral Session 

Date/Time: 15.05.2025 9:35 - 9:40 

Location: Room 14 

M-ES-00015480